Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

Sponsor
Ain Shams University
Study ID
NCT06178874
Status
Completed

Conditions

  • Critical Illness
  • Glycemic Control
  • Insulin

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Insulin Glargine — DRUG
    hyperglycemic control
  • Insulin Degludec — DRUG
    hyperglycemic control
  • Insulin regular — DRUG
    hyperglycemic control

Study Details

The role of ultralong insulin in the control of the blood glucose level in diabetic patients is well known, the current study will discuss the role of ultralong insulin in controlling of hyperglycaemia in critical illness defined as failure or impending failure of an organ

Key Dates

Start date
Dec 1, 2023
Status verified
Aug 2024
Primary completion
May 25, 2024
Completion
Jun 1, 2024

Study Design

Enrollment
90 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: group S
    The random blood sugar in the patients in group S will be managed using regular insulin based on a sliding scale together with an Insulin Glargine, 0.2 units/kg , SC, initially to be titrated as per the clinical situation to be given at 9 PM
  • Active Comparator: Group L
    The random blood sugar in the patients in group L will be managed using regular insulin based on a sliding scale together with an Insulin Degludec 0.2 units/kg, SC, initially to be titrated as per the clinical situation to be given at 9 PM
  • Active Comparator: Group R
    The random blood sugar in the patients in group R will be managed using regular insulin based on a sliding scale

Primary Outcome Measure

hyperglycemic control [ Time Frame: 10 days of ICU stay ]

Related Studies